# BDNF, inflammatory and oxidative levels in treatment-

- naïve ADHD children treated with methylphenidate: An
- **open cohort protocol.**
- 6 Marina Silva de Lucca<sup>1</sup>¶\*, Laira Lopes Tonon<sup>2</sup>&, Jordânia Alves Ferreira<sup>2</sup>&, Bárbara Silva
- 7 Cabral<sup>2&</sup>, Cleuberton Kenedy Oliveira Raimundo<sup>2&</sup>, Sílvia Almeida Cardoso<sup>2¶</sup>, Débora
- 8 Marques de Miranda<sup>3</sup>¶

1

2

4

5

9

17

20

21

22

- 10 <sup>1</sup>Health Sciences Postgraduate Program, Faculty of Medicine, Federal University of
- 11 Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
- <sup>2</sup>Department of Medicine and Nursing, Federal University of Viçosa, Minas Gerais, Brazil.
- 13 <sup>3</sup>Department of Pediatrics, Faculty of Medicine, Federal University of Minas Gerais, Belo
- 14 Horizonte, Minas Gerais, Brazil.
- 15 \* Corresponding author
- 16 E-mail: marinadelucca@ufv.br
- 18 ¶These authors contributed equally to this work.
- 19 &These authors also contributed equally to this work

### **Abstract**

The attention-deficit hyperactivity disorder (ADHD) has a complex etiology, involving the interaction between biological, genetic, and environmental factors. The ADHD pathophysiology remains unknown even though there are hypotheses that inflammatory, hormonal, oxidative and neurotrophic factors are associated. This clinical trial aims to evaluate the contribution of brain derived neurotrophic factor (BDNF), inflammatory and oxidative levels before and after 12 and 24 weeks of methylphenidate use.

### Methods

Patients will be screened upon their entry into Child and Adolescent Psychiatry Teaching Outpatient Clinic of the Medical Course at the Federal University of Viçosa in Minas Gerais, Brazil. One hundred and fifty ADHD treatment-naïve children of both sexes, between 6–14 years old, will be invited to participate, after the ADHD diagnosis by an experienced psychiatrist and the child fulfilling the inclusion criteria. Children and their caregivers will answer questionnaires regarding mental health and the children will undergo neuropsychological tests, physical, nutritional and activity assessment, in addition to blood sampling at baseline, 12 and 24 weeks of methylphenidate use respectively.

### **Discussion**

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

This clinical trial intends to verify how the pharmacological treatment changes the plasma BDNF, inflammatory and oxidative levels in treatment-naïve Brazilian children diagnosed for ADHD. **Trial Registration** Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC). Trial identifier: 13612 Registry name: Níveis de neurotrofina, perfil inflamatório e oxidativo em crianças com TDAH tratadas com metilfenidato. **Administrative information – Spirit 2013 Checklist Title {1}** BDNF, inflammatory and oxidative levels in treatment-naïve ADHD children treated with methylphenidate: An open cohort protocol. **Trial registration** Registry {2a} Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC). Trial identifier: 13612. Registry name: Neurotrophin level, inflammatory and oxidative profile in ADHD children treated with methylphenidate.

Data Set {2b}

65

66

70

71

75

79

81

- The Universal Trial Number (UTN) is U1111-1285-2908.
- Date recruitment began: 23/10/2020; Approximate date when recruitment will be
- 69 completed: 29/11/2022.

# Protocol version {3}

- 72 First version.
- 73 Submitted for registration on Brazilian Registry of Clinical Trials (ReBEC).
- 74 Trial identifier: 13612.

## **76 Funding {4}**

- 77 National Council for Scientific and Technological Development (CNPQ).
- 78 Research Support Foundation of the State of Minas Gerais (FAPEMIG APQ-01023/18)

### 80 Roles and Responsibilities {5}

# **Contributorship {5a}**

- 82 Marina Silva de Lucca. Master in Physical Education and PhD student in Health Sciences,
- 83 Faculty of Medicine, UFMG.
- 84 Laira Lopes Tonon. Medicine student (UFV). Research volunteer member.
- 85 Bárbara Silva Cabral. Medicine student (UFV). Research volunteer member.

Jordânia Alves Ferreira. Medicine student (UFV). Scientific initiation scholarship 86 87 Cleuberton Kenedy Oliveira Raimundo. Medicine student (UFV). Research volunteer 88 member. Silvia Almeida Cardoso. Master and Doctor in Immunology (USP). Associate Professor 89 90 of Nursing and Medicine, Faculty of Medicine, UFV. 91 Débora Marques de Miranda. Master and Doctor in Biochemical and Molecular 92 Pharmacology (UFMG). Associate Professor of Pediatrics, Faculty of Medicine, UFMG. 93 ML is the Chief Investigator; she conceived the study, led the proposal and protocol 94 development. LLT, BSC, JAF and CKOR contributed to development of the proposal and 95 methodology. SC e DM contributed to study design and to development of the proposal 96 and methodology. All authors read and approved the final manuscript. 97 **Sponsor contact information {5b}** 98 Not applicable. 99 100 Sponsor and Funder (5c) 101 102 This funding source had no role in the design of this study and will not have any role 103 during its execution, analyses, interpretation of the data, or decision to submit results. 104 Committees {5d} 105

Principal Investigator and Research Physician

106

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

Design and conduct the clinical appointments: Marina Silva de Lucca. Preparation of protocol and revisions: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda. Organizing steering committee meetings: Marina Silva de Lucca and Débora Marques de Miranda. Publication of study reports: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda. Steering committee The composition of the trial committee includes all authors. Agreement of final protocol: Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Marques de Miranda. All lead investigators will be steering committee members. Recruitment of patients: Laira Lopes Tonon, Bárbara Silva Cabral and Jordânia Alves Ferreira, Cleuberton Kenedy Oliveira Raimundo. Reviewing progress of study and if necessary, agreeing changes to the protocol and/or investigators brochure to facilitate the smooth running of the study: Marina Silva de Lucca and Débora Marques de Miranda. **Trial Management Committee (TMC)** Study planning; Organization of steering committee meetings: Marina Silva de Lucca and Débora Marques de Miranda.

129 Data verification: Marina Silva de Lucca. 130 Endpoint adjudication: Marina Silva de Lucca and Débora Margues de Miranda. 131 **Data Management team** 132 133 Data entry, data verification: Laira Lopes Tonon, Bárbara Silva Cabral, Jordânia Alves Ferreira, Cleuberton Kenedy Oliveira Raimundo and Marina Silva de Lucca. 134 135 **Lead Investigators** 136 Marina Silva de Lucca, Sílvia Almeida Cardoso, and Débora Margues de Miranda. 137 138 interventions, Schedule of enrolment, and 139 assessments 140 141 Introduction 142 143 **Background and rationale {6a}** 144 145 Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder 146 characterized by symptoms of inattention, hyperactivity, and impulsivity that appear in 147 childhood and usually persist into adulthood, causing some degree of dysfunction in daily activities [1,2,3]. The heterogeneous clinical presentations of ADHD are a hallmark of this disorder [4] important negative outcomes are reported, both in terms of morbidity and mortality [3].

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

ADHD has a complex etiology, involving the interaction between genetic, biological and environmental factors. However, its pathophysiology remains unknown [5]. There are hypotheses that inflammatory, oxidative, hormonal, and neurotrophic factors are associated, and they have mutual interactions. [3,6].

Different ADHD risk factors, such as prematurity, paternal smoking, exposure to pesticides and lead may be associated with common pathophysiological pathways, such as inflammation, oxidative stress, and neurotrophic factors. Likewise, intrauterine proinflammatory factors during the gestational period may be associated with restricted intrauterine growth, miscarriage, premature birth, placenta abruption, neurological damage, some of which are risk factors for ADHD [7,8,9, 10, 11, 12]. Neuroinflammation in physiological and pathological conditions may activate microglia, astrocytes, oligodendrocytes, and ependymal cells. In addition, it may increase proteases, glutamate, reactive oxygen species, nitric oxide, chemokines, toxic cytokines, prostaglandins, and may induces infiltration of T and B neutrophils, monocytes/ macrophages and dendritic cells. When activated, these cells release pro-inflammatory cytokines that increase neuroinflammation [13]. Some cytokines are elevated in ADHD, some of which are related to the severity of symptoms [13, 14, 15]. A systematic review on the level of cytokines in peripheral blood showed increased levels of cytokines-interleukin-6 (IL-6) in patients with ADHD, especially in those younger than eighteen years and not on medication, when compared to a healthy control group [13, 16]. However, another systematic review found

no difference in IL-6 levels when comparing children with and without ADHD [17]. Furthermore, patients with ADHD, especially in those younger than eighteen years and not on medication, had lower levels of tumor necrosis factor-alpha human (TNF-alpha) compared to healthy controls [16, 17]. The results regarding cytokines-interleukin-10 (IL-10) were contradictory and may be increased or unchanged in children with ADHD compared to children without the pathology [13, 16, 17]. ADHD treated patients seem to have a decrease in interferon gamma (IFN-gamma) and interleukin-13 (IL-13) levels, compared to those naïve to treatment [13].

Therefore, neuroinflammation could alter the blood-brain barrier, neurotransmitter metabolism, increase oxidative stress, and neurodegeneration [14, 15]. Animals and humans with ADHD show, in different brain structures, an increase in reactive oxygen species without an adequate antioxidant response, resulting in an increase in oxidative stress. This negative imbalance in ADHD may be explained in the central nervous system due to the large consumption of oxygen by neurons associated with an antioxidant defense system of modest action and a constitution rich in lipids. As a result, the brain has difficulty regulating excess reactive oxygen species, making it more susceptible to damage [15, 18, 19, 20, 21, 22]. Therefore, there is evidence of increased oxidative stress in ADHD patients [19, 20, 21 22, 23, 24].

ADHD may be associated with a decrease in ascorbate, catalase, albumin and bilirubin and an increase in uric acid. So, it may contribute to oxidative stress increase [25]. On the other hand, treatment with methylphenidate seems to increase catalase levels. Other study demonstrated that the activity of superoxide dismutase (SOD), an important antioxidant defense enzyme, is lower in patients with ADHD [25].

Increased oxidative stress may be associated with reduced levels of BDNF, as well as reduced oxidative stress with increased BDNF [26]. Therefore, changes in the BDNF expression at critical moments during development may promote a cascade of events interfering with the brain maturation of some regions, being a substrate for altered response to stress in adulthood and development of neuropsychiatric disorders [26]. Another evidence of intense oxidative stress is the modulation of telomere size and shortening during life [27] and telomere shortening is present in ADHD children [28]. So, telomere length may be a potential biomarker of the ADHD symptoms burden in families affected by this neurodevelopmental disorder [29].

Studies with rats have been trying to observe the results of chronic use of methylphenidate in brain cells [30, 31, 32]. Chronic use of methylphenidate in healthy rats caused oxidative damage in the brain of young rats [30]. Furthermore, the chronic use of methylphenidate by adult rats induced oxidative stress and inflammation in the hippocampus, causing cellular damage in this area [31]. Increased oxidative stress was also observed in spontaneously hypertensive adult rats (animal version of ADHD) [32].

In ADHD children and adolescents' study, low levels of nitric oxide were found in baseline, which did not change significantly with the use of methylphenidate over ten weeks [33]. Guney et al. (2015) [33] found that methylphenidate may reduce oxidant levels and increase antioxidant levels in children and adolescents.

Studies have evaluated BDNF levels in individuals with ADHD, comparing them with typical children [17, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51] and after stimulant treatment [40, 45, 50, 51, 52], with divergent results.

Due to the controversial studies and the importance of treating ADHD, this protocol study aims to explain the methodology that will evaluate BDNF, inflammatory and oxidative levels, their associated factors in ADHD treated children for 6 months with methylphenidate.

### **Choice of comparators {6b}**

BDNF, inflammatory markers and oxidative stress levels of the ADHD children will be compared before and after methylphenidate use. Therefore, the same group of children will be compared in three different times: before starting methylphenidate and after 12 and 24 weeks of methylphenidate use. All patients will be in follow-up at the child and adolescent psychiatry outpatient clinic, receiving pharmacological treatment for ADHD. Local health system provides free methylphenidate (generic medication) in the presentation of 10mg, immediate-release tablets.

Control groups (ADHD children without methylphenidate use) will not be possible, because it would be unethical to deprive them of effective treatment, capable of reducing not only morbidity, but also mortality.

### **Objectives {7}**

The objectives of this open cohort clinical trial will be:

1. Evaluate the BDNF, inflammatory and oxidative levels before and after 12 and 24 weeks of methylphenidate use in treatment-naïve ADHD children.

2. Investigate if there is a moderating effect of the sociodemographic data, ADHD presentation, comorbidity presence, caregiver psychopathology, parenting styles, emotional regulation level on BDNF, cytokines and oxidative stress level, telomere length, and other variables from the survey instruments detailed throughout this protocol.

### Trial Design {8}

This trial is designed as an open cohort, single center, with convenience sample.

### Methods: Participants, Interventions, Outcomes

# Study setting {9}

All subjects will be invited to the child psychiatry teaching outpatient clinic at the Federal University of Viçosa (UFV), in the state of Minas Gerais, Brazil.

### Eligibility criteria {10}

# Participants inclusion criteria: {10}

Treatment-naïve ADHD children, of both sex in outpatient treatment; age between complete 6 and incomplete 15 years old. Children must have criteria for ADHD diagnosis according to the DSM-5 and must not have chronic diseases or use of any other medications that may interfere with the immune system or BDNF. Children who need iron or vitamin replacement may be included. The following comorbidities may be included:

oppositional defiant disorder (ODD), tic disorder, enuresis, encopresis, skin picking disorder. Autism spectrum disorder (ASD) level 1, Classification of Diseases and Related Health Problems (ICD) 10 F84.5, could be included if the diagnosis occurs during the study. All parents must sign the free and informed consent form, just like children should also sign the assent form. The terms will be delivered during the initial assessment of the participants, if they wish to participate voluntarily in the research.

## Participants exclusion criteria: {10}

Families and children that refusal to participate in the research or refusal to use stimulant medications; presence of autoimmune, neurodegenerative diseases, and immunodeficiencies; intellectual disability, severe clinical or psychiatric comorbidities, except autism spectrum disorder level 1 (ICD 10 F84.5), ODD, tics, trichotillomania, skin picking disorder, enuresis, and encopresis; previous or current use of stimulants or other psychiatry medications; current use of medications for chronic diseases or that interfere in immune system or BDNF levels (antidepressants for example); girls who have menstruated; stimulant contraindication use.

# **Participant timeline: {13, 14, 15, 18}**

Participants will be included from October 2020 to November 2022, targeting a sample size of 150 children, based on sample calculation with analysis power between 80% and 95% of accuracy. This sample calculation was based on an article of Akay et al., 2017 [37].

They will be forwarded by physicians, schools and psychologists from the city and health region. To reach the sample number, the health units, as well as the municipal education department were communicated about the research and how the children could be referred for screening. There was also publicity on the local radio and the website of the Federal University of Viçosa.

Children who are eligible for the study will be categorized by ADHD presentation, disorder severity, with or without Oppositional Defiant Disorder (ODD), with or without autism spectrum disorder (ASD), at any emotional dysregulation level. Their caregivers will be sorted by parenting style.

Overall, each participant will make 8 to 10 visits during the study period.

The research procedure for participants at each visit are described in Fig. 2.

The initial assessment includes the semi-structured interview Kiddie-Schedule for Affective Disorders and Schizophrenia – Present and Lifetime Version (K-Sads-PL 2013) [53].

To assess the severity of ADHD symptoms, the SNAP-IV scale, Swanson, Nolan e Pelham version [54], and the Assessment Scale of Childhood and Adolescent Behaviors in ADHD in a Family Environment (ETDAH-parents) [55] and ADHD Self-Assessment Scale-Version for Children and Adolescents (ETDAH-Criad) [56] were answered by parents and children. The SNAP-IV scale has 26 items, which also investigates symptoms of a common comorbidity that is Defiant and Oppositional Disorder. [54]. The ETDAH scale has one version for parents and another for the children. [55,56]. The parent subscale has four subscales that investigates symptoms of inattention, hyperactivity/impulsivity, emotional regulation, and adaptive behavior. The

children subscale has 2 subscales that investigates inattention and hyperactivity/impulsivity symptoms.

The diagnosis will be confirmed by a interview done by a Child and Adolescent Psychiatrist. Sociodemographic data was obtained from the Brazil Economic Ranking Criterion and "Background information" part of the K-Sads-PL instrument (K-Sads-PL 2013) [53, 57, 58]. A standard record for the clinical history was constructed with data on pregnancy, childbirth, neuropsychomotor development, and the child's previous and family history.

For the care of children at the outpatient clinic, an anamnesis model was built. This anamnesis also includes a habitual physical activity questionnaire [59], Brazilian food safety scale [60], SISVAN food consumption markers questionnaire [61], food frequency questionnaire [62, 63], bullying questionnaire (Kidscape) [64], measurement questionnaire adherence to treatment [65], CRAFFT/CESARE instrument (Car; Relax; Alone; Forget; Family/Friends; Trouble acronym) [66].

Situations of violence and/or health identified during the research will be duly forwarded to the necessary assistance network, such as justice, other medical specialties, social services, and others. The caregiver is screened for symptoms of depression, anxiety, ADHD, and alcohol use [67, 68, 69, 70]. In case of positive screening, evaluation by an adult psychiatrist will be offered.

## **Interventions {11a, 18}**

### **Screening visits**

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Medical students trained by an experienced child and adolescent psychiatrist and under her supervision, will apply in the first assessment (between one and three visits): Fig. 1. Schedule of enrolment, interventions, and assessments. Multimodal Treatment Assessment Study - Swanson, Nolan e Pelham (MTA-SNAP-IV) scale, that evaluates symptoms of attention deficit/hyperactivity disorder and oppositional defiant disorder in children and adolescents [54] Kiddie Schedule for Affective Disorders and Schizophrenia for School Aged Children – Lifetime Version (K-Sads-PL 2013) [53] Sociodemographic questionnaire, including the Brazil Economic Ranking Criterion and the background information of the K-Sads-PL 2013 [53,57,58] ADHD Behavior Assessment Scale – Parents Version (ETDAH-parents) [55] Bullying questionnaire [64] # Physical activity questionnaire [59] SISVAN food consumption markers [61] Brazilian Food Security Scale (EBIA) [60] Scale of Sleep disorders in children [72] Behavior Inventory for Children and Adolescents (CABI) [73] Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) [74] # Epidemiological Studies Center Depression Scale (CES-D) [67] State-Trait Anxiety Inventory (IDATE) [68] # Adult Self-Report Scale (ASRS-18) [69] Alcohol Use disorders identification test (AUDIT) [70] Standardized psychiatric clinic interview with standard record.

348 Physical examination. 349 350 Psychology students, under supervision of an experienced psychologist in 351 neuropsychology will apply: 352 Scale for screening drug use CRAFFT/CESARE [66] 353 Social Skills Test for Children and Adolescents in School Situation (THAS-C) [75] ADHD Self-Assessment Scale - Version for Children and Adolescents (ETDAH-354 355 CriAd) [56] Standardized and validated psychological tests for the Brazilian population. 356 Non-Verbal test of Children's Reasoning (TNVRI) [76] 357 358 Battery for Attention Assessment (BPA) [77, 78] 359 Five digits teste (FDT) [79] 360 Brief Child Neuropsychological Assessment Instrument (NEUPSILIN-inf) 361 [08] 362 Nutrition's student under supervision of an experienced nutritionist will apply: 363 24-hour food recall [81, 82] 364 365 Assessment points {11a, 18a} 366 367 The assessment points occur in three timepoints: (before baseline methylphenidate initial use) and after 12 and 24 weeks of methylphenidate use. Fig 1 368

369

and 2.

In the first assessment point the blood sample is collected, the family receives psychoeducation about the disorder and its treatment, and the methylphenidate is started.

In the second and third assessment points, all instruments will be applied in screening are reapplied, except K-Sads-PL, sociodemographic questionnaire, standardized psychiatric clinic interview with standard record and NEUPSILIN-inf. In these two timepoints, we will use standardized follow-up anamnesis. Participants will also be clinically evaluated to verify the effect of the treatment (the Clinical Global Impressions (CGI) scale) [83, 84, 85], dose adjustment, the presence of adverse effects, adherence to treatment, clarification of doubts regarding the research, the disorder, and the treatment and reinforce the guidelines regarding the next steps of the study.

## Follow-up visits {11a, 18a}

Participants will also be clinically evaluated at 4, 8 and 18 weeks to verify the effect of the treatment, dose adjustment, the presence of adverse effects, adherence to treatment, clarification of doubts regarding the research, the disorder, the treatment and reinforce the guidelines regarding the next steps of the study.

The number of visits could vary, depending on the patient's individual needs.

# Pharmacotherapy {11b}

Pharmacotherapy will be conducted by experienced child and adolescent psychiatry with primary responsibility for childcare.

Pharmacotherapy starts with a first-line stimulant medication methylphenidate.

[86]. The initial dose will be prescribed as follows: 5mg in the morning and after lunch in

the first week, with adjustment to 10mg at the same time until the next evaluation at 4 weeks. From that moment on, the dose will be titrated to optimize the desired therapeutic effect and minimize undesirable adverse effects. The average dose will be 1 mg/kg/day.

If the child does not tolerate the methylphenidate [87, 88] or does not respond to medication, lisdexamfetamine will be offered. [88] Other formulations may be used such as methylphenidate hydrochloride extended-release capsules or OROS methylphenidate if necessary. In these cases, equivalent doses will be prescribed.

# Blood sample {11a}

A trained nursing professional will collect three samples of venous blood from each patient/volunteer: before medication treatment, 12 and 24 weeks after starting treatment. Blood samples will be kept at a suitable temperature [89] until they are sent to the Biochemistry laboratory of the Department of Biochemistry (UFV). The BDNF [90] and the cytokines levels [91, 92, 93, 94] will be evaluated in blood plasma and the oxidative stress [95,96] level will be evaluated in serum. Telomeres measurements will be made by DNA extraction [27, 28, 29].

# Adherence to intervention protocols {11c, 18b}

To improve adherence to medical visits and research evaluations, nursing technique will confirm the consultation by telephone (calls or WhatsApp messages) the day before. In case of participant absence, contact by phone will be made to offer appointment rescheduling.

The assessment methylphenidate adherence will be by pill count and the Treatment Adherence Measure (MAT) questionnaire [65] in all scheduled visits [97].

### **Modifications (11b)**

The participant will be excluded from the survey if he does not attend the assessment points (blood collection times). If the patient reports the impossibility of attending the assessment visit and is available to reschedule it within a maximum of 15 days, the patient can proceed with the intervention. The patient may miss the visits number 4, 8, 18 and proceed with the intervention, if the regular use of medication continues.

The child will be excluded in case of not tolerating the medication, family withdraws from participation, diagnosis change during follow-up.

The pharmacological intervention may have adverse effects and the child will receive all the necessary and standard care following strictly the clinical protocol. Most adverse effects are usually mild and occur early in treatment [87]. They will be informed and medication will be adjusted accordingly the need.

Participants whose diagnosis on screening differs from the diagnosis of the psychiatry team will be excluded from the study.

### **Concomitant care {11d}**

The treatment can also include speech therapy and occupational therapy if there is a clinical indication. The psych treatment was not available.

Outcomes {12}

#### **Primary outcomes:**

The BDNF levels [37], cytokines and level of oxidative stress (oxidative and antioxidant substances) after treatment with methylphenidate.

#### **Secondary outcomes:**

Behavioral symptoms of Attention Deficit/Hyperactivity Disorder and/or Oppositional Defiant Disorder, emotional regulation level determined by the Multimodal Treatment Assessment Study - Swanson, Nolan e Pelham (MTA-SNAP-IV) scale, which assesses symptoms of attention deficit/hyperactivity disorder and Oppositional Defiant Disorder in children and adolescents, and ETDAH - parents, which assesses emotional regulation.

Cardiovascular parameters on physical examination, as well as body mass index will be recorded.

### **Retention (18b)**

The intervention has the potential to bring great benefits to the child and whole family. The stimulant treatment in ADHD children is associated with reduced morbidity and mortality.

WhatsApp contact will be possible for participants to clarify their doubts, reschedule the appointment, as well as be reminded of the appointments during the period in which they participate in the study.

Moreover, a report containing the child's neuropsychological assessment will be given to the parents. In addition, all children will be under medical supervision at the outpatient clinic, even after the end of the study (UFV).

Post-intervention measures will not be necessary after the twenty-fourth week.

The analysis will be performed with the information obtained up to the time of dropping out in case of child drops out of the study.

# **Data Management {19}**

A part of the data will be entered electronically and registered in REDCap database. A random sampling checking will be done to quality control.

Participant research files are attached to their medical records, so they will be kept for 20 years after the last registration.

### **Statistical Methods (20)**

# Outcomes {20a}

The main analysis strategies will involve group comparison from the three timepoints and trajectory of symptoms and measures across time. Generalized Estimating Equations (GEE) analyses may be done with risk factors and potential

moderators such social deprivation, parental styles, and oppositional symptoms to understand the relationship.

### Additional analyses {20b}

The main additional analyses strategies will involve descriptive data to characterize the studied sample and to observe the correlations between features.

## **Analysis Population and Missing Data {20c}**

Individuals that will not fill the information of the primary outcomes will have the other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative stress at baseline to understand potential populational bias.

Missing data will be handled as necessary for the chosen tests, for GEE for example we will include only individuals with the complete data set for primary outcomes. We will try to retrieve all information by WhatsApp contact.

- **Methods: Monitoring**
- 494 Data Monitoring {21}
- 495 Formal Committee {21a}

Diagnosis data was done by thirteen years experienced child psychiatry and there is a team on UFMG to discuss any doubt prof. DMM and AASJ. They also have 15 years of experience in the field.

## **Interim Analyses (21b)**

Individuals that will not fill the information of the primary outcomes will have the other data analyzed: sociodemographic profile, BDNF dosages, cytokines, and oxidative stress at baseline.

Socioeconomic data will be analyzed to evaluate any potential of sampling bias.

The clinical psychiatric assessment will be done by an experienced child and adolescent psychiatry, and any diagnosis divergence will be informed. Adherence will be considered poor if the child takes less than 2/3 of prescribed doses of methylphenidate.

# **Harms {22}**

Adverse events during the trial will be registered in the child's medical record and communicated to the relevant governmental agencies if necessary.

Assistance in case of adverse events will be guaranteed to the child via the public health system.

# Auditing {23}

All data will be available to audit if necessary. The diagnosis divergence will be evaluated and informed as soon as it is verified.

### **Ethics and Dissemination**

## **Research Ethics Approval {24}**

Approved by the Research Ethics Committee of the Federal University of Minas Gerais. Number: 4.364.744. CAAE: 82870117.0.3001.5149. Written, informed consent to participate will be obtained from all parents, as well as informed assent from the children.

## **Protocol Amendments {25}**

Any modifications to the protocol which may impact on the conduct of the study, potential benefit of the patient or may affect patient safety, will lead to a formal amendment to the protocol with REBEC, the ethics committee and clinical trial publication journal.

## **Consent or Assent {26}**

# **Consent or Assent {26a}**

All parents must sign the free and informed consent form, as well as the children the assent form. The terms will be delivered at the end of the child's screening if the child is considered eligible to be included in the study and they wish to participate voluntarily in the research.

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

**Dissemination Policy {31}** 

**Ancillary Studies (26b)** Not Applicable **Confidentiality {27}** All study-related information will be stored securely at the child's medical record. All local databases will be secured with password-protected access systems. **Declaration of Interests {28}** The author(s) declare(s) that they have no competing interests. Access to Data {29} All researchers will have access to the final trial dataset without any contractual limitations. **Ancillary and Post-trial Care {30}** The children will continue clinical treatment at the child psychiatry outpatient clinic for as long as the family wishes, or they will be discharged or reach the age of 18, when they will be referred to adult services.

# Trial Results {31a}

All research data and personal information will be under responsibility of the researchers to protect confidentiality before, during and after the trial. All parents or guardians' results will be communicated at the end and regarding the trial results.

Trial results will be published at REBEC, regardless of the magnitude or direction of effect. The results will also be reported in an original article and submitted for a relevant journal.

# Authorship {31b}

ML is the Chief Investigator; she conceived the study, led the proposal and protocol development. L, B and J contributed to development of the proposal and methodology. SC e DMM contributed to study design and to development of the proposal and methodology. All authors will read and approve the final manuscript.

# Reproducible Research {31c}

The anonymous data information might be available under request and reasonable demand.

### **Discussion**

Inflammatory, neurotrophic, and oxidative parameters have been associated with the pathophysiology of ADHD. Limitations in the studies varies from small and heterogeneous samples of participants [12], lack of control for variables that may interfere with the results, such as diet, body mass index, short follow-up time, and level of physical activity, are some of these limitations. Moreover, the results are contradictory [98]. Here we propose a protocol trying to make clear clinical and biomarkers in response to medication in a cohort well characterized in a prospective follow up.

Many studies were cross-sectional and retrospective, which allows inferring only an association between inflammation and the disorder and not a causal relationship of pathogenesis [98]. Longitudinal studies are necessary to better establish the possible relationship between ADHD, inflammation, neurotrophic, and oxidative stress [16]. Other important factors to be considered are comorbid mental disorders and potential confounding factors, in addition to being important to observe possible changes in the inflammatory profile after interventions [16].

This trial protocol methodology will follow the participants by 24 weeks, increasing the chance of evaluating the influence of the chronic use of methylphenidate on inflammatory, neurotrophic, and oxidative factors. In addition, there will be evaluation of the child's diet and physical activity through the food recall and the usual physical activity questionnaire, respectively. To reduce hormonal influences of puberty, we will exclude girls who had menarche and limited the age of both sexes to 14 years.

The results may provide information about the pathophysiology of ADHD, being able to collaborate in the identification of biomarkers of the disorder and response to treatment with methylphenidate.

## Acknowledgements

Acknowledgment to the entire Specialized Health Care team (UAES/UFV), Biochemistry and Medicine laboratory (UFV) team, Molecular Medicine laboratory (UFMG) team, scientific initiation students (UFV), psychology students (volunteer member/Univiçosa), nutrition professor and student (UFV), the neuropsychologist Roselaine da Cunha Barros (volunteer member), and the nursing techniques Arieta de Jesus Felisberto Oliveira (UFV) e Ana Cristine Pepe Parabocz (UFV).

### **Appendices**

- **Appendix 1. Informed consent materials {32}**
- 615 Appendix 2. Consent and Assent forms {32}
- 616 Appendix 3. Biorepository constitution {32}

# **Biological specimens {33}**

Collection and analysis of biological samples will follow standard protocols for these procedures in accordance with health surveillance recommendations.

Biorepository term was signed and contains the norms of storage and use in auxiliary and future studies. (Appendix 3)

### References

- 1. Biederman J, Faraone S. Attention-deficit Hyperactivity Disorder. Lancet. 2005;
- 626 (9481):237–248.
- 2. Edition F. Diagnostic and Statistical Manual of Mental Disorders. American
- 628 Psychiatric Association. 2013; 21.
- 3. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment
- of Attention-Deficit Hyperactivity Disorder (ADHD). Annals of Pharmacotherapy.
- 631 2013 Nov;48(2):209–25.
- 4. Drechsler R, Brem S, Brandeis D, Grünblatt E, Berger G, Walitza S. ADHD:
- 633 Current Concepts and Treatments in Children and Adolescents. Neuropediatrics
- 634 [Internet]. 2020 Oct 1;51(5):315–35.
- 5. Núñez-Jaramillo L, Herrera-Solís A, Herrera-Morales WV. ADHD: Reviewing the
- 636 Causes and Evaluating Solutions. Journal of Personalized Medicine. 2021 Mar
- 637 1;11(3):166.
- 6. Dursun S, Demirci E, Kilic E, Ozmen S. A Different View on the Etiopathogenesis
- of Attention-deficit Hyperactivity Disorder from an Inflammation Perspective.
- 640 Clinical Psychopharmacology and Neuroscience. 2021 Feb 28;19(1):145–54.
- 7. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of Comorbidity, Functioning, and
- Service Use for US Children With ADHD, 2007. Pediatrics [Internet]. 2011 Mar
- 643 1;127(3):462–70.
- 8. Heyer DB, Meredith RM. Environmental toxicology: Sensitive periods of
- development and neurodevelopmental disorders. NeuroToxicology. 2017 Jan;
- 646 58:23–41.

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

9. Sogard AS, Mickleborough TD. The therapeutic potential of exercise and caffeine on attention-deficit/hyperactivity disorder in athletes. Frontiers in Neuroscience. 2022 Aug 12;16. 10. Lopresti AL. Oxidative and nitrosative stress in ADHD: possible causes and the potential of antioxidant-targeted therapies. ADHD Attention Deficit and Hyperactivity Disorders. 2015 Apr 19;7(4):237–47. 11. Abdollahi M, Ranjbar A, Shadnia S, Nikfar S, Rezaie A. Pesticides, and oxidative stress: a review. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research [Internet]. 2004 Jun 1;10(6):RA141-147. 12. Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention deficit hyperactivity disorder. Pharmacology Biochemistry and Behavior [Internet]. 2019 Jul; 182:22–34. 13. Anand D, Colpo GD, Zeni G, Zeni CP, Teixeira AL. Attention-Deficit/Hyperactivity Disorder and Inflammation: What Does Current Knowledge Tell Us? A Systematic Review. Front Psychiatry. 2017; 8: 228. 14. Noakes PS, Thomas R, Lane C, Mori TA, Barden AE, Devadason SG, et al. Association of maternal smoking with increased infant oxidative stress at 3 months of age. Thorax [Internet]. 2007 Aug 1 [cited 2021 Aug 1];62(8):714–7. 15. Alvarez-Arellano L, González-García N, Salazar-García M, Corona JC. Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder. Antioxidants. 2020 Feb 21;9(2):176. 16. Misiak B, Wójta-Kempa M, Samochowiec J, Schiweck C, Aichholzer M, Reif A, Samochowiec A, Stańczykiewicz B. Peripheral blood inflammatory markers in

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

patients with attention deficit/hyperactivity disorder (ADHD): A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology Biological Psychiatry. 2022; 118. 17. Chang JP, Mondelli V, Satyanarayanan SK, Chiang YJ, Chen HT, Su KP, Pariante CM. Cortisol, inflammatory biomarkers and neurotrophins in children and adolescents with attention deficit hyperactivity disorder (ADHD) in Taiwan. Brain, behavior, and immunity. 2020; 88:105-113. 18. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience [Internet]. 2006 Apr 1;7(4):295-309. 19. Leffa DT, Bellaver B, de Oliveira C, de Macedo IC, de Freitas JS, Grevet EH, Caumo W, Rohde LA, Quincozes-Santos A, Torres ILS. Increased Oxidative Parameters and Decreased Cytokine Levels in an Animal AttentionDeficit/Hyperactivity Disorder. Neurochemical research, 2017; 42(11): 30843092. DOI: 10.1007/s11064-017-2341-6. 20. Annelies V, Harry R, Annelies B, Tess DB, Nina H. Evaluation of Biomarkers of Oxidative Stress in Attention-Deficit/ Hyperactivity Disorder (ADHD). Journal of Molecular Biomarkers & Diagnosis. 2018;09(03). 21. Joseph N, Zhang-James Y, Perl A, Faraone SV. Oxidative Stress and ADHD. Journal of Attention Disorders. 2013 Nov 14;19(11):915–24. 22. Sezen H, Kandemir H, Savik E, Basmacı Kandemir S, Kilicaslan F, Bilinc H, et al. Increased oxidative stress in children with attention deficit hyperactivity disorder. Redox Report. 2016 Feb 18;21(6):248-53.

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

23. Faraone SV, Asherson P, Banaschewski T, Biederman J, Buitelaar JK, Ramos-Quiroga JA, et al. Attention-deficit/hyperactivity disorder. Nature Reviews Disease Primers [Internet]. 2015 Aug 6; 1:15020. 24. Wynchank D, Bijlenga D, Beekman AT, Kooij JJS, Penninx BW. Adult Attention-Deficit/Hyperactivity Disorder (ADHD) and Insomnia: an Update of the Literature. Current Psychiatry Reports. 2017 Oct 30;19(12). 25. Lu Z, Pu C, Zhang Y, Sun Y, Liao Y, Kang Z, et al. Oxidative Stress and Psychiatric Disorders: Evidence from the Bidirectional Mendelian Randomization Study. Antioxidants. 2022; 11:1386. 26. Asghari A, Hosseini M, Beheshti F, Shafei MN, Mehri S. Inducible nitric oxide inhibitor aminoquanidine, ameliorated oxidative stress, interleukin-6 concentration, and improved brain-derived neurotrophic factor in the brain tissues of neonates born from titanium dioxide nanoparticles exposed rats. The Journal of Maternal-Fetal & Neonatal Medicine. 2018 Jun 17;32(23):3962-73. 27. Drury SS. Theall K. Gleason MM. Smyke AT. De Vivo I. Wong JY et al. Telomere length and early severe social deprivation: linking early adversity and cellular aging. Molecular Psychiatry. 2012; 17(7): 719-27. 28. Pham C. Vryer R. O'Hely M. Mansell T. Burgner D. Collier F et al., On Behalf of The Barwon Infant Study Investigator Group. Shortened Infant Telomere Length Is Associated with Attention Deficit/Hyperactivity Disorder Symptoms in Children at Age Two Years: A Birth Cohort Study. International Journal of Molecular Sciences. 2022; 23(9): 4601.

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

29. Costa DS, Rosa DV, Barros AG, Romano-Silva MA, Malloy-Diniz LF, Mattos P et al. Telomere length is highly inherited and associated with hyperactivity-impulsivity in children with attention deficit/hyperactivity disorder. Frontiers in Molecular Neuroscience. 2015; 8: 28. 30. Martins M, Reinke A, Petronilho F, Gomes K, Dal-Pizzol F, Quevedo J. Methylphenidate treatment induces oxidative stress in young rat brain. Brain research. 2006; 1078: 189-197. 31. Motaghinejad M, Montevalian M, Shabab B. Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats. Neuroscience letters. 2016; 619: 106-113. 32. Comim CM, Gomes KM, Réus GZ, Petronilho F, Ferreira GK, Streck EL, Dal-Pizzol F, Quevedo J. Methylphenidate treatment causes oxidative stress and alters energetic metabolism in an animal model of attention-deficit hyperactivity disorder. Acta Neuropsychiatrica. Cambridge University Press. 2014; 26(2): 96-103. 33. Doneray E, Yazici KU, Yazici IP, Ustundag B. Altered Arginine/Nitric Oxide Pathway in Children Diagnosed Attention Deficit Hyperactivity Disorder, and the Effect of 10 Weeks Methylphenidate Treatment. Clinical Psychopharmacology and Neuroscience. 2022; 20(2): 350-363. 34. Guney E, Cetin FH, Alisik M, Tunca H, Tas Torun Y, Iseri E, et al. Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study. Psychiatry Research. 2015 Sep;229(1-2):310-7.

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

35. Shim SH, Hwangbo Y, Kwon YJ, Jeong HY, Lee BH, Lee HJ, Kim YK. Increased levels of plasma brain-derived neurotrophic factor (BDNF) in children with attention deficit-hyperactivity disorder (ADHD). Progress in NeuroPsychopharmacology and Biological Psychiatry. 2008; 32(8):1824–1828. 36. Sayyah, H. BDNF plasma level in ADHD children: correlation to different symptomatology. Curr Psychiatry [Egypt], 2009; 16, 284-294. 37. Sargin E, Akay AP, Resmi H, Cengizhan SA, Ozek H, Ellidokuz H, Miral S, Orcin E. Evaluation of Serum Brain-Derived Neurotrophic Factor Levels in Children with Attention Deficit Hyperactivity Disorder: Preliminary Data. Archives of Neuropsychiatry. 2012; 49(2): 96+. 38. Scassellati C, Zanardini R, Tiberti A, Pezzani M, Valenti V, Effedri P, Filippini E, Conte S, Ottolini A, Gennarelli M, Bocchio-Chiavetto L. Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit-hyperactivity disorder (ADHD). European child & adolescent psychiatry. 2013; 23(3): 173-177. **39.** Liu L, Li H, Wang Y, Yang L, Qian Q, Wang Y. Association between GUC2C and ADHD: evidence from both categorical and quantitative traits. Psychiatry Research [Internet]. 2014 Dec 15 [cited 2023 Feb 12];220(1-2):708-10. 40. Sahin S, Yuce M, Alacam H, Karabekiroglu K, Say GN, Salis O. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International journal of psychiatry in clinical practice. 2014; 18(4): 280-287.

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

41. Saadat F, Kosha M, Amiry A, Torabi G. Brain-Derived Neurotrophic Factor as a Biomarker in Children with Attention Deficit-Hyperactivity Disorder. Journal of Krishna Institute of Medical Sciences University. 2015; 4(4): 10-17. 42. Imşek Ş, Gençoğlan S, Yüksel T, Kaplan İ, Aktaş H, Alaca R. Evaluation of the Relationship between Brain-Derived Neurotrophic Factor Levels, and the Stroop Interference Effect in Children with Attention-Deficit Hyperactivity Disorder. Noro Psikiyatri Arsivi. 2016; 53(4): 348–352. 43. Bilgic A, Toker A, Isık Ü, Kılınc İ. Serum brain-derived neurotrophic factor, glialderived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder. European child & adolescent psychiatry. 2017; 26(3): 355-363. 44. Reda M, El-Nady HG, Rabie MA, Fawzy R, Adel S, AwadAllah E, Moneim MA. Comparing brain-derived neurotrophic factor levels, intelligence, and memory in clinical subtypes of attention-deficit hyperactivity disorder. Middle East Current Psychiatry. 2016; 23(2): 56-62. 45. Cubero-Millán I, Ruiz-Ramos MJ, Molina-Carballo A, Martínez-Serrano S, Fernández-López L, Machado-Casas I, Tortosa-Pinto P, Ruiz-López A, LunaDel-Castillo JD, Uberos J, Muñoz-Hoyos A. BDNF concentrations and daily fluctuations differ among ADHD children and respond differently to methylphenidate with no relationship with depressive symptomatology. Psychopharmacology. 2016; 234(2): 267–279 46. Taha H, Elsheshtawy E, Mohamed SI, Al-Azazzy O, Elsayed M, Ibrahim SAS. Correlates of brain derived neurotrophic factor in children with attention deficit

782 hyperactivity disorder: A case-control study. Egyptian Journal of Psychiatry. 2017; 783 38(3): 159-163. 47. Wang LJ, Wu CC, Lee MJ, Chou MC, Lee SY, Chou WJ. Peripheral Brain Derived 784 785 Neurotrophic Factor and Contactin-1 Levels in Patients with Attention 786 Deficit/Hyperactivity Disorder. Journal of clinical medicine. 2019; 8(9):1366. 787 48. Yurteri N, Şahin İE, Tufan AE. Altered serum levels of vascular endothelial growth 788 factor and glial-derived neurotrophic factor but not fibroblast growth factor2 in 789 treatment-naive children with attention deficit/hyperactivity disorder. Nordic journal 790 of psychiatry. 2019; 73(4-5): 302-307. 791 49. El Ghamry R, El-Sheikh M, Meguid MA, Nagib S, El Gabry DA. Plasma brain 792 derived neurotrophic factor (BDNF) in Egyptian children with attention deficit 793 hyperactivity disorder. Middle East Current Psychiatry. 2021; 28: 22. 794 50. Gumus C, Yazici IP, Yazici KU, Ustundag B. Increased Serum Brain-derived Neurotrophic Factor, Nerve Growth Factor, Glial-derived Neurotrophic Factor and 795 796 Galanin Levels in Children with Attention Deficit Hyperactivity Disorder, and the 797 Effect of 10 Weeks Methylphenidate Treatment. Clinical psychopharmacology and 798 neuroscience: the official scientific journal of the Korean College of 799 Neuropsychopharmacology. 2022; 20(4): 635–648. 800 51. Akay AP, Resmi H, Güney SA, Erkuran HÖ, Özyurt G, Sargin E, et al. Serum brain-801 derived neurotrophic factor levels in treatment-naïve boys with attention-802 deficit/hyperactivity disorder treated methylphenidate: with 803 observational pretest-posttest study. European Child & Adolescent Psychiatry. 804 2017 Jul 14;27(1):127–35.

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

52. Amiri A, Torabi Parizi G, Kousha M, Saadat F, Modabbernia MJ, Najafi K, Atrkar Roushan Z. Changes in plasma Brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with Attention deficit-hyperactivity disorder (ADHD). Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2013; 47: 20-24. 53. Caye A, Kieling RR, Rocha TB, Graeff-Martins AS, Geyer C, Krieger F, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children -Present and Lifetime Version (K-SADS-PL), DSM-5 update: translation into Brazilian Portuguese. Brazilian Journal of Psychiatry. 2017 Dec;39(4):384–6. 54. Mattos P, Serra-Pinheiro MA, Rohde LA, Pinto D. A Brazilian version of the MTA-SNAP-IV for evaluation of symptoms of attention-deficit/hyperactivity disorder and oppositional-defiant disorder. Revista de psiquiatria do Rio Grande do Sul. 2006;28(3):290-7. 55. Benczik E. Escala de avaliação dos comportamentos infantojuvenis no TDAH em ambiente familiar - Versão para pais (ETDAH-PAIS). 1st ed. Vol. 1. Memnon; 2018. 56.Benczik E. Escala de Autoavaliação do TDAH-Versão para crianças e adolescentes (ETDAH-Criad). 1st ed. Vol. 1. Memnon; 2018. 57. Kamakura W, Mazzon JA. Socioeconomic Stratification Criteria and Classification Tools in Brazil. Revista de administração de empresas. 2016; 56:55-70. 58. Associação Brasileira de Empresas de Pesquisa (ABEP). Alterações na aplicação do Critério Brasil, válidas a partir de 16/04/2018. 2018.

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

59. Fernandes C. Validação do questionário de avaliação de atividade física em crianças com idade entre 9 e 10 anos. Vitória. Tese [Mestrado em Educação Físical – Universidade Federal do Espírito Santo: 2012. 60. Ministério do Desenvolvimento e Combate à fome - Secretaria de Avaliação e Gestão da Informação (MDS-SAGI). Escala brasileira de Insegurança Alimentar (EBIA): análise psicométrica de uma dimensão da Segurança Alimentar e Nutricional. Estudo técnico nº1/2014. 61. Ministério da Saúde. Orientações para avaliação de marcadores de consumo alimentar na atenção básica. 2015, access on feb 11 of 2023]. Avaiable on https://bvsms.saude.gov.br/bvs/publicacoes/marcadores consumo alimentar at encao basica.pdf 62. Gibson RS, Ferguson EL. An interactive 24-hour recall for assessing the adequacy of iron and zinc intakes in developing countries. Washington, DC, and California: International Food Policy Research Institute (IFPRI) and International Center for Tropical Agriculture (CIAT). 2008. 63. Gibson RS, Charrondiere UR, Bell W. Measurement errors in dietary assessment using self-reported 24-hour recalls in low-income countries and strategies for their prevention. Advances in Nutrition. 2017;8(6):980-991. 64. Kidscape: preventing bullying, protecting children. [Accessed on feb 11 of 2013]. Available on http://www.kidscape.org.uk/ Access on: 11/02/2023. 65. Delgado AB, Lima ML. Contribution to Concurrent Validity of Treatment Adherence. Psicologia, Saúde e Doenças. 2001;2(2):81-100.

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

66. Pereira BA de AX, Schram PFC, Azevedo RCS de. Evaluation of the Brazilian version of the CRAFFT/CESARE scale for screening drug use by adolescents. Ciência & Saúde Coletiva. 2016 Jan;21(1):91–9. 67. Silveira DX, Jorge MR. Psychometric properties of the epidemiologic screening scale for depression (CES-D) in clinical and non-clinical populations of adolescents and young adults. Revista de psiguiatria clínica (São Paulo); 1998; 25(5):251-61. 68. Biaggio AMB, Natalício L, Spielberger CD. Desenvolvimento da forma experimental em português do Inventário de Ansiedade Traco-Estado (IDATE). Rio de Janeiro. Arguivos brasileiros de psicologia. 1977; 29 (3): 3144. 69. Leite WB. Avaliação das propriedades psicométricas da escala de autorrelato de sintomas do transtorno do déficit de atenção e hiperatividade ASRS-18. Belo Horizonte. Tese [Mestrado em Neurociências] - Universidade Federal de Minas Gerais. 2011. 70. Mendéz, EB. Uma versão brasileira do AUDIT (Alcohol use disorders identification test). Pelotas. Tese [Mestrado em Epidemiologia] - Universidade Federal de Pelotas. 1999. 71. Costa DS, Paula JJ de, Malloy-Diniz LF, Romano-Silva MA, Miranda DM. Parent SNAP-IV rating of attention-deficit/hyperactivity disorder: accuracy in a clinical sample of ADHD, validity, and reliability in a Brazilian sample. Jornal de Pediatria. 2019 Nov;95(6):736-43. 72. Ferreira V. Escala de distúrbios do sono em crianças: tradução, adaptação cultural e validação. São Paulo. Tese [Mestrado em Ciências] - Universidade Federal de São Paulo - Escola Paulista de Medicina. 2009.

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

73. Cianchetti C, Pasculli M, Pittau A, Campus MG, Carta V, Littarru R, et al. Child and Adolescent Behavior Inventory (CABI): Standardization for age 6-17 Years and First Clinical Application. Clinical Practice & Epidemiology in Mental Health. 2017 Mar 22;13(1):20-6. 74. Oliveira TD, Costa DS de, Albuquerque MR, Malloy-Diniz LF, Miranda DM, de Paula JJ. Cross-cultural adaptation, validity, and reliability of the Parenting Styles and Dimensions Questionnaire – Short Version (PSDQ) for use in Brazil. Revista Brasileira de Psiguiatria. 2018 Jun 11:40(4):410–9. 75. Bartholomeu D. Silva MCR da, Montiel JM. Teste de habilidades sociais para crianças e adolescentes em situação escolar (THAS-C).1st ed. Vol. 1. Memnon; 2014. 76. Pasquali L. Manual Técnico e de Aplicação do Teste Não-Verbal de Raciocínio para Crianças - TNVRI. 1st ed. Vol. 1. São Paulo - SP. Vetor editora; 2005. P.1-82. 77. Rueda FJM. BPA - Bateria psicológica para avaliação da atenção. 1st ed. Vol. 1. São Paulo - SP. Vetor editora; 2013. 78. Rueda FJM, Monteiro RM de. Psychological Battery for Attention Assessment (BPA): performance of different age groups. Psico-USF. 2013;18(1):99–108. 79. Sedó M, Paula JJ de, Malloy-Diniz LF. Five Digit Test. 1st ed. Vol. 1. Hogrefe; 2015. 80. Salles JF de, Fonseca RP, Rodrigues CC, Mello CB, Barbosa T, Miranda MC. Development of the Child Brief Neuropsychological Assessment Battery NEUPSILIN-INF. Psico-USF. 2011; 16(3): 297-305.

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

81. Crispim SP et al. Manual fotográfico de quantificação alimentar. 2017. Curitiba: Universidade Federal do Paraná. 2017. 82. International Dietary Data Expansion Project. 24-hour Dietary Recall (24HR). [Accessed feb 11 20231. Available on of on https://inddex.nutrition.tufts.edu/data4diets/data-source/24-hour-dietary-recall-<u>24hr</u> 83. Guy W. Clinical Global Impression (CGI): ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare. 1976. 84. Busner J. Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (edgmont). 2007;4(7): 29-37. 85. Lima MS de et al. The Portuguese version of the Clinical Global Impression -Schizophrenia Scale: validation study. Revista Brasileira de Psiquiatria. 2007;29(3):246-9 86. Advokat C, Scheithauer M. Attention-deficit hyperactivity disorder (ADHD) stimulant medications as cognitive enhancers. Frontiers in Neuroscience. 2013;7(82). 87. Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews. 2015 Nov 25. 88. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy, and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738.

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

89. Lin SK, Tsai SM, Huang JC, Lee SC, Wu SH, Wu SH, et al. Effects of storage time and temperature on the stability of glutathione in deproteinized blood samples. Journal of Food and Drug Analysis. 2020 Jul 14:14(2). 90. Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB. Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Scientific Reports. 2019; 9: 9655. 91. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunology. 2009;10(1):52. 92. Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Stability of cytokines, chemokines and soluble activation markers in unprocessed blood stored under different conditions. Cytokine. 2016 Aug; 84:17-24. 93. Gong Y, Liang S, Zeng L, Ni Y, Zhou S, Yuan X. Effects of blood sample handling procedures on measurable interleukin 6 in plasma and serum. Journal of Clinical Laboratory Analysis. 2019 May 26;33(7). 94. Chiswick EL, Duffy E, Japp B, Remick D. Detection and Quantification of Cytokines and Other Biomarkers. Methods in Molecular Biology [Internet]. 2011 Dec 21: 844:15— 30. 95. Jansen EHJM, Beekhof PK, Cremers JWJM, Viezeliene D, Muzakova V, Skalicky J. Short-Term Stability of Biomarkers of Oxidative Stress and Antioxidant Status in Human Serum. ISRN Biomarkers. 2013 Jun 18; 2013:1–5.

96. Jansen EHJM, Beekhof PK, Viezeliene D, Muzakova V, Skalicky J. Long-term stability of oxidative stress biomarkers in human serum. Free Radical Research. 2017 Nov 28;51(11-12):970–7.
97. Osterberg L, Blaschke T. Adherence to Medication. The New England Journal of Medicine. 2005; 353:487-97.
98. Cortese S et al. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry. 2023; 22(1): 129-149.

## **Supporting Information**

950 S1\_File. SPIRIT Checklist.

Fig 1. Schedule of enrolment, interventions, and assessments.


		STUDY PERIOD								
		Enrolment Allocation Post-allocation							Close- out	
	TIMEPOINT**	-t,	t <sub>o</sub>	<b>t</b> ₁ baseline	t₂ ₄ sem	<b>t</b> ₃ 8 sem	<b>t₄</b> 12 sem	<b>t</b> ₅ 18 sem	<b>t</b> <sub>6</sub> 24 sem	
	ENROLMENT:									
	Eligibility screen	Х								
medRxiv pr (which v	reprint doi: https://doi.org/10.1101/2023.03.03.23286780; this version ras not certified by peer review) is the author/funder, who has gran It is made available under a 15 2 1 4 5.0	posted March 5, 2023 ted medRxiv a license nternations dicense .	The copyright holder to display the preprint i	or this preprint n perpetuity.						
	K-Sads-PL	х								
	Sociodemographic data	х								
	Allocation		х							
		INTE	RVENTIONS	:						
	Child Questionnaires									
	ADHD Self-Assessment Scale – Version for Children and Adolescents (ETDAH-Cri Ad)			х			Х		х	
	ADHD Behavior Assessment Scale - Parental Version (ETDAH-parents)			х			Х		х	
	SNAP-IV			х			х		х	
	Psychiatry interview (standard record)			х	Х	Х	Х	х	х	
	Physical Examination			х	Х	х	х	х	х	
	Measure Treatment Adherence (MTA) and pill count			х	Х	Х	Х	х	х	
	24-hour food recall			х			Х		х	
	SISVAN food consumption markers			х			Х		х	
	Bullying questionnaire (Kidscape)			х			Х		х	
	Physical activity questionnaire			х			х		х	

	Scale of sleep disorders in children			х			х		х
	Social Skills Test for Children and Adolescents in School Situation (THAS-C)			х			х		х
	CRAFFT/CESARE (scale for screening drug use)			х			х		х
	CABI (Behavior Inventory for Children and Adolescents)			х			х		х
	Caregivers Questionnaires								
	Parenting Styles and Dimensions	- Curogivo	Quoditoriii	A.A			.,		, ,
	Questionnaire – Short Version (PSDQ)			Х			Х		Х
medRxiv p (which v	reprint doi: https://doi.org/10.1101/2023.03.03.23286780; this version vas house it light by per texts of the author(tender, who have grant lit is made available under a CC-BY 4.0	posted March 5, 2023 ted medRxiv a license International license .	. The copyright holder to display the preprint i	for this preprint in perpetitity.			Х		Х
	Epidemiological Studies Center Depression Scale (CES-D)			х			х		х
	State-Trait Anxiety Inventory (IDATE)			х			х		х
	Audit (Alcohol Use Disorder Identification Test)			х			х		х
	Asr18 (Adult Self-Report Scale)			х			х		х
	Neuropsychological Assessment								
	N	europsycho	nogical ASS						
	TNVRI			Х			Х		Х
	ВРА			Х			Х		Х
	FDT			х			Х		Х
	Neupsilin			х					
	Pharmacological Intervention								
	Methylphenidate (short acting)			х	х	х	х	х	х
		_							
	Sample Blood								
	BDNF			Х			Х		Х
	Cytokines			х			х		х
	Oxidative stress			х			х		х
	ASSESSMENTS:								
	ACCESSIMENTS.								

First trial assessment		х			
Second trial assessment				х	
Third trial assessment					х

medRxiv preprint doi: https://doi.org/10.1101/2023.03.03.23286780; this version posted March 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Fig. 2. The participants visit.



- \* Assessment points (Psychiatric clinical follow-up, Nutrition assessment, Neuropsychological assessment, Sample Blood, Questionnaires and Scales)
- \*\* Methylphenidate prescription after first blood sample.
- \*\*\*Children who finished the trial times will be transferred to the general outpatient clinic of child psychiatry at the UFV medical school.